Predicting Response to Lenalidomide in Myelodysplastic Syndrome
Author Information
Author(s): Azra Raza, BL Ebert, N Galili, P Tamayo, J Bosco, R Mak
Hypothesis
Can a molecular signature predict response to lenalidomide in patients with myelodysplastic syndrome?
Conclusion
The study identified a gene expression signature that can predict which patients will respond to lenalidomide treatment.
Supporting Evidence
- The gene expression response signature was enriched in genes involved in erythroid differentiation.
- The application of lenalidomide to primary non-MDS CD34+ cells promoted erythroid differentiation.
Takeaway
Scientists found a way to tell which patients with a blood disease called myelodysplastic syndrome will get better with a medicine called lenalidomide.
Methodology
The authors used gene expression profiling to identify a molecular signature in patients without Chromosome 5q deletions.
Limitations
The study is small and may not be robust for predicting responses in a larger, more diverse group.
Participant Demographics
Patients with myelodysplastic syndrome, specifically those without Chromosome 5q deletions.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website